Cargando…
Medications and Alcohol Craving
The use of medications as an adjunct to alcoholism treatment is based on the premise that craving and other manifestations of alcoholism are mediated by neurobiological mechanisms. Three of the four medications approved in the United States or Europe for treating alcoholism are reported to reduce cr...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Institute on Alcohol Abuse and Alcoholism
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760374/ https://www.ncbi.nlm.nih.gov/pubmed/10890816 |
_version_ | 1783453855088902144 |
---|---|
author | Swift, Robert M. |
author_facet | Swift, Robert M. |
author_sort | Swift, Robert M. |
collection | PubMed |
description | The use of medications as an adjunct to alcoholism treatment is based on the premise that craving and other manifestations of alcoholism are mediated by neurobiological mechanisms. Three of the four medications approved in the United States or Europe for treating alcoholism are reported to reduce craving; these include naltrexone (ReVia(™)), acamprosate, and tiapride. The remaining medication, disulfiram (Antabuse(®)), may also possess some anticraving activity. Additional medications that have been investigated include ritanserin, which has not been shown to decrease craving or drinking levels in humans, and ondansetron, which shows promise for treating early onset alcoholics, who generally respond poorly to psychosocial treatment alone. Use of anticraving medications in combination (e.g., naltrexone plus acamprosate) may enhance their effectiveness. Future studies should address such issues as optimal dosing regimens and the development of strategies to enhance patient compliance. |
format | Online Article Text |
id | pubmed-6760374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | National Institute on Alcohol Abuse and Alcoholism |
record_format | MEDLINE/PubMed |
spelling | pubmed-67603742019-10-02 Medications and Alcohol Craving Swift, Robert M. Alcohol Res Health Articles The use of medications as an adjunct to alcoholism treatment is based on the premise that craving and other manifestations of alcoholism are mediated by neurobiological mechanisms. Three of the four medications approved in the United States or Europe for treating alcoholism are reported to reduce craving; these include naltrexone (ReVia(™)), acamprosate, and tiapride. The remaining medication, disulfiram (Antabuse(®)), may also possess some anticraving activity. Additional medications that have been investigated include ritanserin, which has not been shown to decrease craving or drinking levels in humans, and ondansetron, which shows promise for treating early onset alcoholics, who generally respond poorly to psychosocial treatment alone. Use of anticraving medications in combination (e.g., naltrexone plus acamprosate) may enhance their effectiveness. Future studies should address such issues as optimal dosing regimens and the development of strategies to enhance patient compliance. National Institute on Alcohol Abuse and Alcoholism 1999 /pmc/articles/PMC6760374/ /pubmed/10890816 Text en http://creativecommons.org/publicdomain/mark/1.0/ Unless otherwise noted in the text, all material appearing in this journal is in the public domain and may be reproduced without permission. Citation of the source is appreciated. |
spellingShingle | Articles Swift, Robert M. Medications and Alcohol Craving |
title | Medications and Alcohol Craving |
title_full | Medications and Alcohol Craving |
title_fullStr | Medications and Alcohol Craving |
title_full_unstemmed | Medications and Alcohol Craving |
title_short | Medications and Alcohol Craving |
title_sort | medications and alcohol craving |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760374/ https://www.ncbi.nlm.nih.gov/pubmed/10890816 |
work_keys_str_mv | AT swiftrobertm medicationsandalcoholcraving |